Suchergebnisse - "De Giorgi, Ugo"

PubPharm (39)

1

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Motzer, R. | Porta, C. | Eto, M. | +134

2

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype : A Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Lorusso, D. | Raspagliesi, F. | Ronzulli, D. | +20

3

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

enthalten in: The New England journal of medicine | 2024

von Powles, T. | Valderrama, B. | Gupta, S. | +122

4

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations : cohort 2 of the randomized phase III THOR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Siefker-Radtke, A. | Matsubara, N. | Park, S. | +113

5

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc) : a randomised, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2024

von Oaknin, A. | Gladieff, L. | Martínez-García, J. | +117

6

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis results from a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Grande, E. | Arranz, J. | De Santis, M. | +20

7

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis from a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Bamias, A. | Davis, I. | Galsky, M. | +21

8

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Freedland, S. | de Almeida Luz, M. | De Giorgi, U. | +17

CommentIn: N Engl J Med. 2024 Jan 4;390(1):90. - PMID 38169497

9

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

10

A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study : the ITACA Score

enthalten in: Minerva urology and nephrology | 2023

von Fornarini, G. | Rebuzzi, S. | Buti, S. | +18